

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
	SC16-040 (HL/Nivolumab)	Treatment	SHORE: Dr. Kathleen Yost	Josh Haveman joshua.haveman@spectrumhealth.org (616) 486-7624
A051701	Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-hit and Double-expressing Lymphomas	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1826	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (ADCETRIS) plus AVD in Patients (AGE>= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A051301	A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma of the Activated B-Cell Subtype	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ANHL12P1	COG-ANHL12P1: A Randomized Phase II study of <u>Brentuximab</u> Vedotin and <u>Crizatinib</u> in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL.) Patients Must be <22 Years of Age	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1608	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

EA4181	<p>A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine + Rituximab + High Dose Cytarabine (BR/CR), 2.) Bendamustine + Rituximab + High Dose Cytarabine + Acalabrutinib (BR/CR-A) and 3.) Bendamustine + Rituximab + Acalabrutinib (BR-A) in Patients >70 years old with Untreated Mantle Cell Lymphoma</p>	Treatment	<p>CRCWM Physician Investigators</p>	<p>CRCWM (616) 391-1230 www.crcwm.org</p>
AALL1731	<p>A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)</p>	Treatment	<p>CRCWM Physician Investigators</p>	<p>CRCWM (616) 391-1230 www.crcwm.org</p>
CytomX	<p>CTMX-M-2029-001: A Phase I/II, First-in-human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-Cell Lymphomas</p>	Treatment	<p>START Midwest Investigators</p>	<p>START Midwest (616) 954-5554</p>